Cancer diagnosis & prognosis最新文献_第10页

Laparoscopic Colectomy for Cecal Cancer and Intestinal Malrotation: A Case Report. 腹腔镜结肠切除术治疗盲肠癌和肠旋转不良：病例报告。

Cancer diagnosis & prognosis Pub Date : 2024-05-03 eCollection Date: 2024-05-01 DOI: 10.21873/cdp.10318

Rie Mizumoto, Norikatsu Miyoshi, Teruo Inoue, Sumiko Nakagawa, Yuki Sekido, Tsuyoshi Hata, Atsushi Hamabe, Takayuki Ogino, Hidekazu Takahashi, Mitsuyoshi Tei, Yoshinori Kagawa, Mamoru Uemura, Yuichiro Doki, Hidetoshi Eguchi

{"title":"Laparoscopic Colectomy for Cecal Cancer and Intestinal Malrotation: A Case Report.","authors":"Rie Mizumoto, Norikatsu Miyoshi, Teruo Inoue, Sumiko Nakagawa, Yuki Sekido, Tsuyoshi Hata, Atsushi Hamabe, Takayuki Ogino, Hidekazu Takahashi, Mitsuyoshi Tei, Yoshinori Kagawa, Mamoru Uemura, Yuichiro Doki, Hidetoshi Eguchi","doi":"10.21873/cdp.10318","DOIUrl":"https://doi.org/10.21873/cdp.10318","url":null,"abstract":"Background/aim: Intestinal malrotation (IM) often remains undetected until adulthood, being discovered during testing or surgery for other comorbidities. Preoperative understanding of this anatomical abnormality is crucial.Case report: An 80-year-old woman presented with cecal cancer. Three-dimensional computed tomography (CT) revealed that the cecum was located at the midline of the abdominal cavity, the duodenum did not cross the midline, and the ileocolic vein ran to the left. Clinically diagnosed with stage IVc cecal cancer complicated by IM, the patient underwent laparoscopic surgery. The ascending colon and cecum were not fixed to the retroperitoneum. The duodenum lacked the second, third, and fourth portions and the small bowel was distributed on the left and right sides of the abdominal cavity. Adhesions had shortened the mesentery, which were released close to their normal positions.Conclusion: Although laparoscopic surgery is superior to open surgery in terms of securing the field of view in a narrow space, providing a magnifying effect, and minimal invasiveness, it has a limited field of view and is inferior in terms of grasping the overall anatomy, which may be disadvantageous in cases of anatomical abnormalities. Colorectal cancer with IM is rare; however, the rate of preoperative diagnosis seems to be increasing thanks to improvements in diagnostic imaging, such as three-dimensional CT scans. In this study, we also reviewed 49 cases of colorectal cancer associated with IM.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11062165/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140874008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Skeletal Muscle Mass Index Reduction Rate as a Prognostic Indicator for Patients Undergoing Pancreatectomy for Pancreatic Cancer. 骨骼肌质量指数降低率作为胰腺癌胰腺切除术患者的预后指标

Cancer diagnosis & prognosis Pub Date : 2024-05-03 eCollection Date: 2024-05-01 DOI: 10.21873/cdp.10324

Junya Mita, Takashi Maeda, Eiji Tsujita, Naotaka Hashimoto, Ranma Fujikawa, Yuki Ono, Akihiro Sakai, Shinichi Tanaka, Rumi Matono, Takahiro Ohmine, Takuro Kometani, Shohei Yamaguchi, Kozo Konishi, Kenkichi Hashimoto

{"title":"Skeletal Muscle Mass Index Reduction Rate as a Prognostic Indicator for Patients Undergoing Pancreatectomy for Pancreatic Cancer.","authors":"Junya Mita, Takashi Maeda, Eiji Tsujita, Naotaka Hashimoto, Ranma Fujikawa, Yuki Ono, Akihiro Sakai, Shinichi Tanaka, Rumi Matono, Takahiro Ohmine, Takuro Kometani, Shohei Yamaguchi, Kozo Konishi, Kenkichi Hashimoto","doi":"10.21873/cdp.10324","DOIUrl":"https://doi.org/10.21873/cdp.10324","url":null,"abstract":"Background/aim: There have been many studies on skeletal muscle depletion before surgery, and skeletal muscle depletion is a known risk factor for poor prognosis. However, reports on the association between changes in skeletal muscle mass and prognosis after surgery for pancreatic cancer are very few.Patients and methods: The data of 137 patients who underwent pancreatectomy for pancreatic cancer between 2005 and 2022 were reviewed. Muscle areas were measured at the third lumbar vertebral level, and skeletal muscle mass index (SMI) reduction rates were calculated. Patients were divided into two groups using receiver operating characteristic (ROC) curve analysis based on the SMI reduction rate with a cutoff of 14% reduction rate. The clinicopathological factors, overall survival (OS), and recurrence-free survival (RFS) were compared between the two groups. Survival rates were analyzed both univariately and multivariately to clarify the factors associated with poor prognosis after pancreatectomy.Results: A total of 102 patients met the inclusion criteria. SMI reduction rate ≥14% significantly correlated with advanced age and higher incidence of postoperative complications. In the multivariate Cox regression analysis, preoperative prognostic nutritional index (PNI) <40 and SMI reduction rate ≥14% were significantly associated with poor OS. Tumor size ≥3.0 cm, preoperative neutrophile-lymphocyte ratio ≥3.0, and SMI reduction rate ≥14% were significantly associated with poor RFS.Conclusion: The rate of skeletal muscle mass reduction after pancreatic surgery is an independent prognostic factor for survival in patients with pancreatic cancer.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11062158/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140861061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy of Recombinant Methioninase on Late-stage Patient Cancer in the Histoculture Drug Response Assay (HDRA) as a Potential Functional Biomarker of Sensitivity to Methionine-restriction Therapy in the Clinic. 组织培养药物反应试验（HDRA）中重组甲硫氨酸酶对晚期癌症患者的疗效作为临床上对甲硫氨酸限制疗法敏感性的潜在功能性生物标记。

Cancer diagnosis & prognosis Pub Date : 2024-05-03 eCollection Date: 2024-05-01 DOI: 10.21873/cdp.10314

Yutaro Kubota, Masato Sasaki, Qinghong Han, Chihiro Hozumi, Takuya Tsunoda, Robert M Hoffman

{"title":"Efficacy of Recombinant Methioninase on Late-stage Patient Cancer in the Histoculture Drug Response Assay (HDRA) as a Potential Functional Biomarker of Sensitivity to Methionine-restriction Therapy in the Clinic.","authors":"Yutaro Kubota, Masato Sasaki, Qinghong Han, Chihiro Hozumi, Takuya Tsunoda, Robert M Hoffman","doi":"10.21873/cdp.10314","DOIUrl":"https://doi.org/10.21873/cdp.10314","url":null,"abstract":"Background/aim: The present study utilized the three-dimensional histoculture drug response assay (HDRA) to determine the efficacy of recombinant methioninase (rMETase) on tumor tissue resected from patients with late-stage cancer, as a functional biomarker of sensitivity to methionine restriction therapy.Patients and methods: Resected peritoneal-metastatic cancer, including colorectal cancer, pancreatic cancer, ovarian cancer, and pseudomyxoma were placed on Gelform in RPMI 1640 medium for seven days and treated with rMETase from 2.5 U/ml to 20 U/ml. Cell viability was determined using the MTT assay. A total of 48 patients with late-stage cancer underwent testing for rMETase responsiveness using the HDRA.Results: Colorectal cancer and pseudomyxoma had the highest sensitivity to rMETase. Pancreatic and ovarian cancer also responded to rMETase, but to a lesser degree.Conclusion: Patients with tumors with at least 40% sensitivity to rMETase in the HDRA are being considered as candidates for methionine restriction therapy, which includes the use of rMETase in combination with a low-methionine diet.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11062157/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140873870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Assessment of Tumor Markers in Renal Transplant Recipients. 评估肾移植受者的肿瘤标志物

Cancer diagnosis & prognosis Pub Date : 2024-05-03 eCollection Date: 2024-05-01 DOI: 10.21873/cdp.10319

Shota Fukae, Kazuaki Yamanaka, Sayoko Yonemoto, Takahiro Yoshida, Masahiro Nakagawa, Naohiko Fujii, Hidefumi Kishikawa

{"title":"Assessment of Tumor Markers in Renal Transplant Recipients.","authors":"Shota Fukae, Kazuaki Yamanaka, Sayoko Yonemoto, Takahiro Yoshida, Masahiro Nakagawa, Naohiko Fujii, Hidefumi Kishikawa","doi":"10.21873/cdp.10319","DOIUrl":"https://doi.org/10.21873/cdp.10319","url":null,"abstract":"Background/aim: Malignant tumors are diagnosed using various methods, including diagnostic imaging methods. The measurement of tumor markers is commonly used because of its noninvasiveness and convenience. Furthermore, it is known that the excretion and metabolism of some tumor markers are affected by impaired renal function. In the present study, we investigated the effect of improved renal function on pre-and post-transplantation changes in tumor marker levels [carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP), carbohydrate antigen 19-9 (CA19-9), and prostate-specific antigen (PSA)] in renal transplant recipients.Patients and methods: A total of 116 renal transplant recipients, who had not been diagnosed with malignancies between January 2012 and December 2019, were included, and tumor markers were investigated.Results: CEA showed a significant decrease after kidney transplantation, regardless of the dialysis type (3.6→2.6 ng/ml, p<0.001), while other tumor markers showed a significant increase (AFP: 3.6→3.7 ng/ml; CA19-9: 16.2→19.5 U/ml; PSA: 0.95→1.05 ng/ml; all p<0.05). Pre- and postoperative eGFR ratios and postoperative liver function were identified as factors influencing the postoperative CEA and CA19-9 values, while PSA was influenced by the duration of dialysis. No statistically significant factors were found for AFP levels.Conclusion: Caution should be exercised when investigating tumor markers in patients with renal dysfunction, as tumor marker levels may vary depending on the pathophysiology of each patient.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11062155/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140861745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pseudomyxoma Peritonei: A Challenging Clinical Diagnosis. Case Report and Review of the Literature. 腹膜假肌瘤：具有挑战性的临床诊断。病例报告与文献综述。

Cancer diagnosis & prognosis Pub Date : 2024-03-03 eCollection Date: 2024-03-01 DOI: 10.21873/cdp.10308

Nikolaos Tsoukalas, Konstantinos Tsapakidis, Maria Tolia, Maria Kiakou, Michalis Galanopoulos, Eleni Aravantinou-Fatorou, Panagiotis Baxevanos, Vasileios Papadopoulos, Chrysovalantis Tountziaris, Michalis Nikolaou, Konstantinos Kamposioras

{"title":"Pseudomyxoma Peritonei: A Challenging Clinical Diagnosis. Case Report and Review of the Literature.","authors":"Nikolaos Tsoukalas, Konstantinos Tsapakidis, Maria Tolia, Maria Kiakou, Michalis Galanopoulos, Eleni Aravantinou-Fatorou, Panagiotis Baxevanos, Vasileios Papadopoulos, Chrysovalantis Tountziaris, Michalis Nikolaou, Konstantinos Kamposioras","doi":"10.21873/cdp.10308","DOIUrl":"10.21873/cdp.10308","url":null,"abstract":"Background: Pseudomyxoma peritonei (PMP) is a clinical entity of subtle onset abdominal pain, ascites, and distention associated with characteristic imaging. In most cases, laparoscopic exploration will give the definitive diagnosis and histopathologic verification. However, usually there are difficulties in the diagnosis of this disease.Case report: Herein, we present a case of a 51-year-old female who developed ascites over 5 months. An investigational laparotomy established the diagnosis of PMP, after the discovery of a mucinous, grey-brown tumor that was CK20 positive and CK7 negative. Subsequently, chemotherapy with oxaliplatin combined with 5-FU (FOLFOX4 regimen), was initiated and the patient survived for 30 months. We also present a comprehensive review of the English literature concerning the different symptoms and radiological findings of this rare entity. According to the literature review, 35 cases of PMP with different clinical and radiological findings have been described. In the majority of the cases, ultrasound, computed tomography or magnetic resonance imaging was orientating towards a proper diagnosis before a diagnostic laparotomy.Conclusion: The combination of a clinical picture with the characteristic imaging findings enables a prompt diagnosis of PMP, making prognosis more favorable.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10905292/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140023536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Systemic Chemotherapy for Advanced Hepatocellular Carcinoma in Patients With Child-Pugh class B. 对 Child-Pugh 分级 B 的晚期肝细胞癌患者进行全身化疗。

Cancer diagnosis & prognosis Pub Date : 2024-03-03 eCollection Date: 2024-03-01 DOI: 10.21873/cdp.10295

Akifumi Kuwano, Masayoshi Yada, Kosuke Tanaka, Yuta Koga, Shigehiro Nagasawa, Akihide Masumoto, Kenta Motomura

{"title":"Systemic Chemotherapy for Advanced Hepatocellular Carcinoma in Patients With Child-Pugh class B.","authors":"Akifumi Kuwano, Masayoshi Yada, Kosuke Tanaka, Yuta Koga, Shigehiro Nagasawa, Akihide Masumoto, Kenta Motomura","doi":"10.21873/cdp.10295","DOIUrl":"10.21873/cdp.10295","url":null,"abstract":"Background/aim: Numerous agents, including immune checkpoint inhibitors, are now available for hepatocellular carcinoma (HCC) treatment. Most trials involving systemic chemotherapy have included patients with Child-Pugh class A, while excluding or minimally enrolling those with Child-Pugh class B, due to liver dysfunction-related mortality. This study aimed to identify prognostic factors for survival in Child-Pugh class B patients receiving sorafenib (SOR), lenvatinib (LEN), atezolizumab plus bevacizumab (ATZ+BEV), or hepatic arterial infusion chemotherapy (HAIC).Patients and methods: From December 2003 to June 2023, 137 patients with advanced HCC receiving systemic chemotherapies (SOR: n=43, LEN: n=16, ATZ+BEV: n=18, HAIC: n=60) were enrolled.Results: Overall survival (OS) and response rates did not differ significantly across treatments (SOR: 8.3 months, LEN: 10.2 months, ATZ+BEV: 8.5 months, HAIC: 7.3 months). Patients on HAIC and LEN had a lower rate of discontinuing treatment within three months compared to those on ATZ+BEV and SOR. HAIC was associated with fewer changes in ALBI score and better preservation of liver function. Multivariate logistic regression identified serum α-fetoprotein >400 ng/ml [hazard ratio (HR)=1.94; p=0.001], tumor count >5 (HR=1.55; p=0.043), and Child-Pugh score (HR=2.53; p=0.002) as independent predictors of OS.Conclusion: OS and response rates were similar across systemic chemotherapies. Prognosis for HCC in Child-Pugh class B patients was associated with liver function, necessitating further research for optimal treatment.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10905279/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140023538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Outcomes in Patients With DLBCL Treated With R-CHOP According to Radiotherapy and Interim PET Response. 根据放疗和中期 PET 反应确定接受 R-CHOP 治疗的 DLBCL 患者的临床疗效

Cancer diagnosis & prognosis Pub Date : 2024-03-03 eCollection Date: 2024-03-01 DOI: 10.21873/cdp.10304

Jesang Yu, Sung Ui Jung, Jin Hyuk Choi, Sungmin Jun, Ho Sup Lee, Dajung Kim

{"title":"Clinical Outcomes in Patients With DLBCL Treated With R-CHOP According to Radiotherapy and Interim PET Response.","authors":"Jesang Yu, Sung Ui Jung, Jin Hyuk Choi, Sungmin Jun, Ho Sup Lee, Dajung Kim","doi":"10.21873/cdp.10304","DOIUrl":"10.21873/cdp.10304","url":null,"abstract":"Background/aim: Interim positron emission tomography/computed tomography (PET/CT) scan is a valuable tool for assessing the early metabolic response to chemotherapy in diffuse large B-cell lymphoma (DLBCL). Although radiotherapy is an effective treatment for lymphoma, especially for local tumor control, the role of consolidative radiotherapy in diffuse large B-cell lymphoma (DLBCL) remains controversial. This study analyzed the clinical outcomes of patients with DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), stratified by interim PET response and the administration of radiotherapy.Patients and methods: We conducted a retrospective review of 107 patients with DLBCL treated with R-CHOP chemotherapy between January 2012 and December 2016. Overall survival (OS), recurrence-free survival (RFS), and freedom from disease progression (FFDP) were calculated using the Kaplan-Meier method and compared using the log-rank test.Results: Forty-six patients were included in this analysis, with a median follow-up time of 65.9 months (range=4.7-125.3 months). The metabolic CR (mCR) group exhibited superior OS, RFS, and FFDP compared with the metabolic PR (mPR) group (p=0.003, p=0.001, and p=0.008, respectively). The 1-, 2-, and 5-year FFDP were 92.97%, 89.3%, and 85.6%, respectively, in the mCR group and 78.6%, 61.9%, and 44.2%, respectively, in the mPR group. In subgroup analysis, the FFDP of the mPR group without radiotherapy was significantly lower than that of the other groups (mCR with/without radiotherapy and mPR with radiotherapy, p=0.001).Conclusion: Consolidative radiation therapy using interim PET can benefit patients who do not achieve mCR. Further well-controlled prospective randomized trials are required.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10905293/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140023577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Post-treatment Neutrophil/Lymphocyte Ratio Is a Prognostic Factor in Head and Neck Cancers Treated With Nivolumab. 治疗后中性粒细胞/淋巴细胞比率是头颈癌患者接受 Nivolumab 治疗的预后因素之一

Cancer diagnosis & prognosis Pub Date : 2024-03-03 eCollection Date: 2024-03-01 DOI: 10.21873/cdp.10305

Yoh-Ichiro Iwasa, Ryosuke Kitoh, Yoh Yokota, Kentaro Hori, Mariko Kasuga, Takashi Kobayashi, Shintaro Kanda, Yutaka Takumi

{"title":"Post-treatment Neutrophil/Lymphocyte Ratio Is a Prognostic Factor in Head and Neck Cancers Treated With Nivolumab.","authors":"Yoh-Ichiro Iwasa, Ryosuke Kitoh, Yoh Yokota, Kentaro Hori, Mariko Kasuga, Takashi Kobayashi, Shintaro Kanda, Yutaka Takumi","doi":"10.21873/cdp.10305","DOIUrl":"10.21873/cdp.10305","url":null,"abstract":"Background/aim: Inflammation and nutrition-based biomarkers, such as the neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), lymphocyte/monocyte ratio (LMR), C-reactive protein/albumin ratio (CAR), prognostic nutritional index (PNI), systemic immune inflammation index (SII), and systemic inflammation response index (SIRI), have prognostic value for several types of malignancies. Markers that precisely reflect the prognosis of patients with head and neck cancers (HNCs) treated with immune-checkpoint inhibitors remain unclear. This retrospective study aimed to investigate the prognostic value of hematological markers before and after treatment with nivolumab in patients with recurrent or metastatic HNC (RM-HNC).Patients and methods: We evaluated the clinical data of 44 patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab between April 2017 and April 2023 at Shinshu University Hospital. Values of hematological biomarkers (NLR, LMR, PLR, CAR, PNI, SII, and SIRI) were calculated before and 4-6 weeks after nivolumab initiation. Receiver operating characteristic curves were constructed to determine the cutoff values of pre- and post-treatment markers for overall survival (OS) and progression-free survival (PFS).Results: Among all pre- and post-treatment markers, post-treatment NLR showed the highest area under the curve (AUC=0.702). A high post-treatment NLR (cutoff value, 4.01) was associated with a poor OS (p=0.027) and a tendency for shorter PFS (p=0.117). Multivariate analysis showed that a high post-treatment NLR was significantly associated with poor OS (p=0.026).Conclusion: A high post-treatment NLR was associated with poor response to nivolumab in head and neck cancers.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10905290/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140023532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Analysis of Oral Squamous Cell Carcinoma: A Single-institution Experience. 口腔鳞状细胞癌的临床分析：单一机构的经验。

Cancer diagnosis & prognosis Pub Date : 2024-03-03 eCollection Date: 2024-03-01 DOI: 10.21873/cdp.10294

Rina Jiromaru, Ryuji Yasumatsu, Mioko Matsuo, Kazuki Hashimoto, Ryunosuke Kogo, Takashi Nakagawa

{"title":"Clinical Analysis of Oral Squamous Cell Carcinoma: A Single-institution Experience.","authors":"Rina Jiromaru, Ryuji Yasumatsu, Mioko Matsuo, Kazuki Hashimoto, Ryunosuke Kogo, Takashi Nakagawa","doi":"10.21873/cdp.10294","DOIUrl":"10.21873/cdp.10294","url":null,"abstract":"Background/aim: There is limited evidence about the significance of head and neck surgical observation at the time of diagnosis and follow-up of oral cancer after treatment. The aim of this study was to elucidate the prognosis and prognostic factors of oral squamous cell carcinoma (OSCC), analyze cases of double cancers, and highlight the importance of examinations during both diagnosis and post-treatment for OSCC.Patients and methods: We performed a retrospective analysis of 272 OSCC cases treated for the first time during a 10-year period from April 2013 to March 2023 at Kyushu University Hospital. Information obtained in the clinical setting, such as age, stage, prognosis, and presence of double cancers, was used in the analysis.Results: The mean age of 272 patients was 69 years; 203 patients were males and 69 were females. The most common oral cancer sites were the tongue (54.4%). The 5-year overall survival rate was 63.8%. Double cancer was found in 93 patients (34.2%). Synchronous double cancers were found in 38 patients (14.0%), 50% of whose cancer types were head and neck cancers.Conclusion: We analyzed 272 OSCC patients treated at the Kyushu University Hospital, and the results were comparable to those reported by other institutions. Tumor site, age, and stage were identified as prognostic factors. Half of the patients with synchronous double cancers had head and neck cancer, and 3-10% of patients with double cancers after treatment for OSCC also had head and neck cancer, suggesting the importance of otorhinolaryngological observation at the time of the diagnosis and after treatment.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10905289/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140023576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of Atezolizumab Plus Bevacizumab Versus Modified Lenvatinib Therapy in Child-Pugh A Unresectable Hepatocellular Carcinoma. 评估阿特珠单抗联合贝伐单抗与改良型仑伐替尼治疗Child-Pugh A型不可切除肝细胞癌的效果

Cancer diagnosis & prognosis Pub Date : 2024-03-03 eCollection Date: 2024-03-01 DOI: 10.21873/cdp.10297

Michio Kimura, Shiori Yamada, Makiko Go, Satoshi Yasuda, Hidenori Toyoda, Eiseki Usami

{"title":"Evaluation of Atezolizumab Plus Bevacizumab Versus Modified Lenvatinib Therapy in Child-Pugh A Unresectable Hepatocellular Carcinoma.","authors":"Michio Kimura, Shiori Yamada, Makiko Go, Satoshi Yasuda, Hidenori Toyoda, Eiseki Usami","doi":"10.21873/cdp.10297","DOIUrl":"10.21873/cdp.10297","url":null,"abstract":"Background/aim: Atezolizumab/bevacizumab (Atez/BV) and lenvatinib (LEN) are the recommended first-line treatments for patients with unresectable hepatocellular carcinoma (HCC). Previous reports have suggested that the tolerability and therapeutic efficacy of LEN could be enhanced by modifying its administration method. Therefore, this study compared the efficacy and safety of Atez/BV, the standard LEN therapy (standard LEN), and modified LEN therapy (modified LEN).Patients and methods: The overall survival (OS) and the rate of discontinuation due to adverse events (AEs) were compared between groups treated with Atez/BV (n=36), standard LEN (n=30), and modified LEN (n=11).Results: Discontinuation due to AEs was required in 22.2%, 23.3%, and 9.1% of patients in the Atez/BV, standard LEN, and modified LEN groups (p=0.485). The median OS for the Atez/BV, standard LEN, and modified LEN groups was 523 [95% confidence interval (CI)=163-818], 382 (95%CI=330-547), and 604 (95% CI=257-656) days, respectively (log-rank test, p=0.949).Conclusion: Atez/BV and the standard and modified LEN regimens showed comparable efficacy and safety.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10905284/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140023581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0